Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer

Y Zhu, Y Xia, G Ren, M Wang, X Zeng… - Chinese medical …, 2010 - mednexus.org
Background A retrospective analysis of clinical data were conducted reviewing patients who
were given erlotinib at Peking Union Medical College (PUMC) Hospital from May 2005 to …

[HTML][HTML] EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population

C Gridelli, A Rossi - Journal of Thoracic Disease, 2012 - ncbi.nlm.nih.gov
chemotherapy in terms of PFS, main endpoint of the trial, with 9.7 versus 5.2 months,
respectively (HR 0.37, 95% CI 0.25-0.54). ORRs were 58% and 15%, respectively. OS data …

Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)

F Kayali, MA Janjua, DA Laber, DM Miller… - Journal of Clinical …, 2009 - ascopubs.org
e19077 Background: There is laboratory evidence that digoxin sensitizes cancer cells to the
induction of apoptosis by chemotherapy. Inhibition of the Na/K-ATPase enzyme by ouabain …

Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials

H Gao, X Ding, D Wei, P Cheng, X Su, H Liu… - Anti-Cancer …, 2011 - journals.lww.com
Erlotinib is a potent reversible HER1/epidermal growth factor receptor tyrosine kinase
inhibitor with single-agent activity in patients with non-small cell lung cancer. The aim of this …

[PDF][PDF] Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients

AC Grigorescu, C Bala - J BUON, 2013 - jbuon.com
Purpose: The purpose of the present trial was to investigate whether clinical benefit can be
obtained by concurrent administration of erlotinib with gemcitabine as first-line treatment in …

A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer

KA Gold, JJ Lee, N Harun, X Tang, J Price… - The …, 2014 - academic.oup.com
Background. EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC).
In preclinical models, combining EGFR and Src inhibition has additive synergistic effects …

[HTML][HTML] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

JJ Yang, Q Zhou, HH Yan, XC Zhang, HJ Chen… - British journal of …, 2017 - nature.com
Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …

Review of erlotinib in the treatment of advanced non-small cell lung cancer

KN Ganjoo, H Wakelee - Biologics: Targets and Therapy, 2007 - Taylor & Francis
Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …

Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects

G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …

Reviewing the safety of erlotinib in non-small cell lung cancer

M Reck, T Mok, J Wolf, D Heigener… - Expert opinion on drug …, 2011 - Taylor & Francis
Importance of the field: Erlotinib, a potent inhibitor of EGFR activity, is approved as a
monotherapy for the treatment of advanced NSCLC and in combination with gemcitabine for …